Literature DB >> 15361909

Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0.

M Sakiyama1, M Kami, A Hori, O Imataki, T Hamaki, N Murashige, K Kobayashi, Y Kishi, R Kojima, S-W Kim, E Kusumi, K Yuji, S Miyakoshi, S Mori, R Tanosaki, S Taniguchi, Y Takaue.   

Abstract

Acute regimen-related toxicity (RRT) is minimal in reduced-intensity stem-cell transplantation (RIST). However, the Seattle RRT grading (Bearman et al), developed in the context of conventional-intensity transplantation, is frequently applied to RIST. We compared the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0 with the Seattle criteria after RIST in 86 patients. RRT within 30 days of transplant graded by both sets of criteria were significantly associated with the outcome confirming the predictive value of both the systems. A total of 15 patients died of disease progression, and 12 of transplant-related mortality: RRT (n = 2), graft-versus-host disease (GVHD) (n = 7), infection (n = 1), and others (n = 2). GVHD-related deaths primarily resulted from infections after steroid treatment (n = 6) and bronchiolitis obliterans (n = 1). This study shows that NCI-CTC is appropriate in toxicity evaluation of RIST, and that its application to RIST enables a toxicity comparison between RIST and other types of cancer treatments. Since GVHD is a significant problem in RIST, modifications are required to evaluate immunological complications following RIST.

Entities:  

Mesh:

Year:  2004        PMID: 15361909     DOI: 10.1038/sj.bmt.1704673

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.

Authors:  Yoshihiro Inamoto; Taku Oba; Koichi Miyamura; Seitaro Terakura; Akane Tsujimura; Yachiyo Kuwatsuka; Masahiro Tokunaga; Masanobu Kasai; Makoto Murata; Tomoki Naoe; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  In vivo engineering of bone tissues with hematopoietic functions and mixed chimerism.

Authors:  Yu-Ru Shih; Heemin Kang; Vikram Rao; Yu-Jui Chiu; Seong Keun Kwon; Shyni Varghese
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

3.  PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer.

Authors:  Hanqun Zhang; Shisheng Tan; Chunju Fang; Qi Zhang; Xue Cao; Yuncong Liu
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

4.  Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Authors:  Xavier Poiré; Andrew Artz; Richard A Larson; Justin Kline; Olatoyosi Odenike; Elizabeth Rich; Lucy Godley; Wendy Stock; Koen van Besien
Journal:  Leuk Lymphoma       Date:  2009-01

5.  High proportions of CD3+ T cells in grafts delayed lymphocyte recovery and reduced overall survival in haploidentical peripheral blood stem cell transplantation.

Authors:  Ying Zhang; Caili Guo; Chunhong Sun; Ying Chen; Huachao Zhu; Jieying Xi; Mei Zhang; Pengcheng He; Xiaoning Wang
Journal:  Mol Clin Oncol       Date:  2020-04-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.